How Hastings was paid
$3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Paul J. HastingsChief Executive Officer | $674,384 | $236,250 | $1,711,957 | $344,947 | $10,500 | $2,978,038 |
| Nadir Mahmood, Ph.D.President | $543,250 | $155,000 | $434,646 | $252,611 | $10,500 | $1,396,007 |
| Shawn Rose, M.D., Ph.D.Chief Medical Officer and Head of Research and Development | $316,591 | $709,300 | $189,720 | — | $9,162 | $1,224,773 |
What changed and why
- $3MPaul J. Hastings received total compensation of $2,978,038 in 2025, representing a decrease from $3,985,445 in 2024.
- The decrease in CEO total compensation was primarily driven by lower stock and option award values.
- Following a March 2025 reduction in force, the company implemented a one-time retention option program.
- Dr. Shawn Rose joined the company as Chief Medical Officer and Head of Research and Development on June 23, 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.